Hot on Roche’s heels, Merck spells out mixed Keytruda data in adjuvant NSCLC
Is Merck ready to crack open a major new market for its PD-1 star?
The pharma giant said so as it released full data from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
